New immunotherapy duo aims to outdo chemo for common lymphoma
NCT ID NCT07634471
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated follicular lymphoma will take part. The study will check safety, how well the cancer responds, and whether the new combination helps people live longer without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1045 (immunotherapy) combined with rituximab (targeted therapy)
What this could lead to
If successful, this could offer a more effective, chemotherapy-free first-line treatment for follicular lymphoma, potentially improving remission rates and delaying disease progression.
What could go wrong
This is an early-to-mid-stage trial (phase 2/3) with 960 participants. The experimental combination may not prove superior to standard chemo, and side effects from immunotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hacettepe Universite Hastaneleri ( Site 1110)
RECRUITINGAnkara, 06230, Turkey (Türkiye)
Contact Phone: •••-•••-••••
-
Hadassah Medical Center ( Site 0701)
RECRUITINGJerusalem, 9112001, Israel
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall de Hebron ( Site 0903)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
SCRI Oncology Partners ( Site 7000)
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0702)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••